Biobehavioral Measurement Core

摘要 生物行为测量核心（安娜马奎斯，CL） 本项目的目的是阐明中年心血管疾病的神经生物学差异， 疾病（CVD）风险。主要结局包括两大领域：（1）临床前血管疾病和功能障碍 （2）心脏代谢风险。次要结局是心血管事件、高血压和2型糖尿病。 所有项目（P）都假设心血管疾病风险的共同近端介质，包括健康行为（例如， 物质使用、习惯饮食、身体活动和睡眠），以及自主神经功能的候选生物调节剂。 对照、全身炎症、内皮和HPA轴功能以及氧化应激。启用统一 数据收集和P之间的协同作用，核心B团队将收集、验证和监控共享计划 结局和介质，将数据传输至核心C，并按受试者方案连续报告受试者 坚持核心A。核心B还将监督所有生物行为测量的质量保证， 集中储存与纵向测试有关的生物标本，提供咨询和教育， 生物行为措施，所有P队，并协助解释结果。对于纵向分析，所有 在随访评估时重新获得T1时获得的满足P 1-3目标的测量值，以及 将获得新的或扩展的测量结果，这对于捕获前哨预测因子是可行的和有利的， 影响CVD风险的介质和结果。我们将收集899名被招募到P 1-3的人的数据。核心B是 由行为免疫学实验室的主任Margaret博士领导， 处理和储存。她由一名核心医疗主任和门诊部负责人协助。医疗 主任是一名医生，负责监督参与者报告的临床诊断和事件， 作为参与者安全监测和相关风险缓解策略。门诊部部长将 监督在该计划队列中通常获得的所有流动措施，包括生态 瞬时评估日志数据、动态血压和体动记录数据。

ABSTRACT Biobehavioral Measurement Core (Anna Marsland, CL) The objective of this Program Project is to elucidate the neurobiology of midlife disparities in cardiovascular disease (CVD) risk. Primary outcomes lay in 2 broad domains: (1) preclinical vascular disease and dysfunction and (2) cardiometabolic risk. Secondary outcomes are incident CVD events, hypertension, and type 2 diabetes. All projects (P's) postulate common proximal mediators of CVD risk, including health behaviors (e.g., substance use, customary diet, physical activity, and sleep), as well as candidate biomediators of autonomic control, systemic inflammation, endothelial and HPA-axis function, and oxidative stress. To enable uniform data collection and synergy across Ps, the Core B team will collect, verify and monitor shared Program outcomes and mediators, transfer data to Core C, and continuously report subject-by-subject protocol adherence to Core A. Core B will also oversee the quality assurance of all biobehavioral measures, provide centralized storage of biological specimens relevant to longitudinal testing, offer consultation and education on biobehavioral measures to all P teams, and assist with interpreting findings. For longitudinal analyses, all measurements obtained at T1 that address the aims of P's 1-3 will be re-obtained at follow-up assessments, and new or expanded measurements will be obtained as is feasible and advantageous to capture sentinel predictors, mediators and outcomes impacting CVD risk. We will collect data on 899 people recruited to P's 1-3. Core B is led by Dr. Marsland, Director of the Behavioral Immunology Laboratory where biological samples will be processed and stored. She is assisted by a Core Medical Director and Ambulatory Division Leader. The Medical Director is a physician who will assume oversight of participant-reported clinical diagnoses and events, as well as participant safety monitoring and associated risk mitigation strategies. The Ambulatory Division Leader will provide oversight of all ambulatory measures commonly obtained in the Program cohorts, including ecological momentary assessment diary data, ambulatory blood pressure, and actigraphy data.